<?xml version='1.0' encoding='utf-8'?>
<document id="19249953"><sentence text="Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction."><entity charOffset="37-48" id="DDI-PubMed.19249953.s1.e0" text="sitagliptin" /><entity charOffset="49-59" id="DDI-PubMed.19249953.s1.e1" text="lovastatin" /><pair ddi="false" e1="DDI-PubMed.19249953.s1.e0" e2="DDI-PubMed.19249953.s1.e0" /><pair ddi="false" e1="DDI-PubMed.19249953.s1.e0" e2="DDI-PubMed.19249953.s1.e1" /></sentence><sentence text="A 75-year-old woman with diabetes mellitus, hypertension, and hyperlipidemia came to the emergency department with generalized and upper-extremity weakness; she had experienced a fall 2 months earlier" /><sentence text=" On admission, her drug therapy included lovastatin 40 mg/day, controlled-release diltiazem 240 mg/day, and glimepiride 1 mg/day"><entity charOffset="41-51" id="DDI-PubMed.19249953.s3.e0" text="lovastatin" /><entity charOffset="108-119" id="DDI-PubMed.19249953.s3.e1" text="glimepiride" /><pair ddi="false" e1="DDI-PubMed.19249953.s3.e0" e2="DDI-PubMed.19249953.s3.e0" /><pair ddi="false" e1="DDI-PubMed.19249953.s3.e0" e2="DDI-PubMed.19249953.s3.e1" /></sentence><sentence text=" Nineteen days earlier, sitagliptin 100 mg/day had been started; it was discontinued 2 weeks later, and glimepiride was begun"><entity charOffset="24-35" id="DDI-PubMed.19249953.s4.e0" text="sitagliptin" /><entity charOffset="104-115" id="DDI-PubMed.19249953.s4.e1" text="glimepiride" /><pair ddi="false" e1="DDI-PubMed.19249953.s4.e0" e2="DDI-PubMed.19249953.s4.e0" /><pair ddi="false" e1="DDI-PubMed.19249953.s4.e0" e2="DDI-PubMed.19249953.s4.e1" /></sentence><sentence text=" A cardiology consultation performed on the day of admission determined that a markedly elevated creatine kinase-myocardial band isoenzyme level and borderline-high troponin I level were diagnostic of rhabdomyolysis secondary to statin use" /><sentence text=" Because the patient had been taking lovastatin for the past 12 years, the possibility that the rhabdomyolysis may have been caused by a drug interaction between lovastatin and a concomitant drug was evaluated"><entity charOffset="37-47" id="DDI-PubMed.19249953.s6.e0" text="lovastatin" /><entity charOffset="162-172" id="DDI-PubMed.19249953.s6.e1" text="lovastatin" /><pair ddi="false" e1="DDI-PubMed.19249953.s6.e0" e2="DDI-PubMed.19249953.s6.e0" /><pair ddi="false" e1="DDI-PubMed.19249953.s6.e0" e2="DDI-PubMed.19249953.s6.e1" /></sentence><sentence text=" As it had been 10 months since her last dosage adjustment of diltiazem, it was unlikely that the statin-induced rhabdomyolysis was precipitated by diltiazem" /><sentence text=" Use of the Drug Interaction Probability Scale to determine the strength of a lovastatin-sitagliptin interaction indicated a possible association (score of 4)"><entity charOffset="78-88" id="DDI-PubMed.19249953.s8.e0" text="lovastatin" /><entity charOffset="89-100" id="DDI-PubMed.19249953.s8.e1" text="sitagliptin" /><pair ddi="false" e1="DDI-PubMed.19249953.s8.e0" e2="DDI-PubMed.19249953.s8.e0" /><pair ddi="false" e1="DDI-PubMed.19249953.s8.e0" e2="DDI-PubMed.19249953.s8.e1" /></sentence><sentence text=" Multiple drug interactions have been reported with lovastatin"><entity charOffset="52-62" id="DDI-PubMed.19249953.s9.e0" text="lovastatin" /></sentence><sentence text=" To our knowledge, however, this is the first case report of a possible sitagliptin-lovastatin interaction that may have caused rhabdomyolysis"><entity charOffset="72-83" id="DDI-PubMed.19249953.s10.e0" text="sitagliptin" /><entity charOffset="84-94" id="DDI-PubMed.19249953.s10.e1" text="lovastatin" /><pair ddi="false" e1="DDI-PubMed.19249953.s10.e0" e2="DDI-PubMed.19249953.s10.e0" /><pair ddi="false" e1="DDI-PubMed.19249953.s10.e0" e2="DDI-PubMed.19249953.s10.e1" /></sentence><sentence text=" Studies must be performed to further evaluate the in vivo effect of sitagliptin on the cytochrome P450 3A4 enzyme system and to elucidate other mechanisms that may potentiate such a drug-drug interaction"><entity charOffset="69-80" id="DDI-PubMed.19249953.s11.e0" text="sitagliptin" /></sentence><sentence text=" In the meantime, however, clinicians should be aware of this possible drug interaction" /><sentence text="" /></document>